Actively Recruiting
The Revitalize Trial Evaluating Vaginal Fractional CO2 Laser Therapy versus Placebo for Vaginal Dryness in Breast Cancer Survivors
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-10-19
250
Participants Needed
3
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating vaginal fractional CO2 laser therapy compared to a placebo procedure to treat vaginal dryness in breast cancer survivors experiencing genitourinary syndrome of menopause GSM. This phase III trial aims to assess if the laser treatment improves vaginal dryness severity and related symptoms while monitoring potential side effects. GSM results from low estrogen levels and can be caused by aging, menopause, or breast cancer treatments like chemotherapy or endocrine therapy. Participants are randomly assigned in a 21 ratio to either receive vaginal fractional CO2 laser therapy or a placebo procedure lasting 20 to 30 minutes every 6 weeks, for a total of three treatments. After the treatment phase, patients who received the placebo may choose to receive the laser therapy. Follow-up visits occur at 6 weeks, and then 3, 6, 12, 18, and 24 months after the last procedure to monitor outcomes and safety. During the study, participants complete questionnaires assessing vaginal dryness severity, vaginal discomfort during sexual activity, and quality of life. Researchers will track changes in these symptoms up to 24 months post-treatment and monitor any adverse events related to the laser therapy. Participation involves multiple visits for treatments and follow-ups over approximately two years, with assessments based on patient reports and safety evaluations.
CONDITIONS
Brief Title
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
Research Team
M
Maryam Lustberg, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here